How does adipotide work?

Adipotide, also written FTPP, is an experimental two-part peptide. This site's profile says one part latches onto a protein (prohibitin) on the blood vessels that feed fat tissue. The other part damages those cells' power plants (mitochondria), which cuts off blood supply to white fat. It is listed as leaving the body quickly (a short half-life). Its molecular weight is about 2,600 daltons. This site's review found two studies, both non-human. It is not FDA approved and has never come into general medical use. In obese rhesus monkeys, it caused 7.4 to 14.7% weight loss in four weeks, with kidney effects that grew with the dose and went away after. The first mouse work used a homing tag (CKGGRAKDC) attached to a cell-killing peptide. Those animal findings do not transfer into a counted human mechanism. The kidney damage seen in monkeys is why it has not moved forward. This FAQ does not invent a human mechanism. Full record at /compounds/adipotide.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.